Hospices are required to provide pharmaceuticals under the Medicare Hospice Benefit. Since there are no data describing these costs for hospice programs, this study analyzes data from a cross-sectional survey of 34 hospices concerning their pharmaceutical cost trends. Most respondents reported higher pharmaceutical-related costs between 1998 and 2002, but a significant minority reported that their costs had decreased. Pharmaceutical costs varied by patient setting, but long-acting opioids and continuous-infusion delivery systems were the two most significant contributors. A variety of mechanisms were employed to control drug costs.
Jost TS:Public financing of pain management: Leaky umbrellas and ragged safety nets. J Law Med Ethics. 1998; 26(4): 290-307.
2.
Levit K, Smith C, Cowan C, et al.: Trends in US health care spending, 2001. Health Aff. 2003; 22(1): 154-164.
3.
Shiah ND, Hoffman JM, Vermeulen LC, et al.: Projecting future drug expenses—2003. Am J Health Syst Pharm. 2003; 60(2): 137-149.
4.
Cheung L, Fitch K, Pyenson B:The Costs of Hospice Care: An Actuarial Evaluation of the Medicare Hospice Benefit. New York: Millman USA, Inc., 2001. Commissioned by the National Hospice and Palliative Care Organization. NHPCO Web site. Available at www.nhpco.org/files/public/TheCostsofHospiceCare.pdf. Accessed October 2, 2003.
5.
NHPCO National Data Set Summary Report—Part 1. National Hospice and Palliative Care Web site. Available at www.nhpco.org/files/members/2002NationalDataSet.pdf. Accessed Sept 16, 2003.
6.
Lunney JR, Lynn J, Foley DJ, et al:Patterns of functional decline at the end of life. JAMA. 2003; 289(18): 2387-2392.
7.
Teno JM, Weitzen S, Fennell ML, et al.: Dying trajectory in the last year of life: Does cancer trajectory fit other diseases? J Palliat Med. 2001; 4(4): 457-464.
8.
General Accounting Office: More Beneficiaries Use Hospice, Yet Many Factors Contribute to Shorter Stays (GAO/HEHS-00-182). Washington, September 2000.
9.
Rich MW, Shore B:Dobutamine for patients with end-stage heart failure in a hospice program? J Palliat Med. 2003; 6(1): 93-97.
10.
Pass SE, Dusing ML:Current and emerging therapy for primary pulmonary hypertension. Ann Pharmacother. 2002; 36(9): 1414-1423.
11.
Beckwith S, Thomas OV:Hospice pharmacy: Everything you need to know [unpublished]. Presented at NHPCO’s 18th Management and Leadership Conference, 2003.
12.
Kinzbrunner B: Hospice Pharmacy Management [unpublished]. Presented at NHPCO’s 17th Management and Leadership Conference, 2002.
13.
Arter SG, Berry JI:The provision of pharmaceutical care to hospice patients: Results of the National Hospice Pharmacist Survey. J Pharm Care Pain Symptom Control. 1993; 1(1): 25-42.
14.
Arter SG, Berry JI: Cost Effective Strategies to Improve Drug Therapy Outcomes. International Pharmaceutical Abstracts accession number 32-14451. Abstract presented at APhA Annual Meeting, 1995.
15.
McPherson ML: Evaluation of Economic Outcomes in Palliative Care Patients Receiving NSAID Therapy per Protocol. International Pharmaceutical Abstracts accession number 39-03578. Abstract presented at ASPH Midyear Clinical Meeting, 2001.
16.
Treadway AK, Topping DL, Broyles JE, et al.: Development and Implementation of a Pilot Project Exploring a Pharmacist’s Role in Medication Management within a Hospice Setting. International Pharmaceutical Abstracts accession number 37-05265. Abstract presented at ASHP Annual Meeting, 2000.
17.
Keely JL:Pharmacist scope of practice. Ann Intern Med. 2002; 136(1): 79-85.
